Dublin, July 20, 2017 -- The "RNAi Technology - 2017: Insect and Pest Control, Disease and Weed Control, Crop Enhancement, Formulation and Delivery, Patents, Safety and Regulations, Company Profiles, Specialist Institutes" report has been added to Research and Markets' offering.
Employed as a research tool in entomology and as a means of crop protection and pest control, RNA interference (RNAi) technology is a natural process used to silence' genes - a way of reducing or switching off the activity (or expression) of individual genes.
With a major drive to tackle resistance to insecticides, RNAi technology has important defence and regulatory functions in animals, plants and fungi. Producing crop hybrids and varieties with enhanced yield and quality characteristics is also a major application of this technology, and superior traits brought to market include improved oil composition (high oleic acid), reduced lignin content (for greater digestibility of feed by livestock), the elimination of browning when slicing apples and potatoes, and reduced potential for acrylamide production when frying potatoes.
This report provides an overview of RNAi technology and its use in new product development for improved crop varieties, crop protection and pest control. It details company and product profiles, and activities and pipelines of specialist companies and research institutes engaged in RNAi technology. It also reviews key safety considerations for the technology, as well as commentary and positions of European and US regulatory authorities.
Other focus areas of this report include research undertaken and commentary about future sprayable RNAi technology, patent applications claiming the use of the technology for disease control, and newer commercial drivers for RNAi applications in crop protection as a possibility of overcoming herbicide resistance in weeds. Increasing crop production in responses to abiotic stress (such as drought) is also considered.
Key Topics Covered:
Executive Summary
1. Introduction
1.1 Summary
1.2 Introduction
1.3 Scope
1.4 Technical background
1.4.1 History
1.4.2 Science of RNAi
1.4.2.1 The flow of information in the cell: from DNA to protein via mRNA
1.4.2.2 Discovery of RNA interference
1.4.2.3 Role of RNAi in nature
1.4.2.4 The RNAi process and machinery
1.5 Safety and regulations
1.5.1 Safety
1.5.1.1 Environment
1.5.1.2 Food and feed
1.5.1.3 Non-target organisms
1.5.2 Regulations
1.5.2.1 Europe
1.5.2.2 USA
1.6 References and resources
2. RNAi for controlling insects and other pests
2.1 Summary
2.2 Introduction
2.2.1 Role of RNAi technology
2.2.2 Progress in using RNAi technology
2.3 Coleoptera
2.4 Lepidoptera
2.5 Diptera
2.6 Hemiptera
2.7 Nematodes
2.8 Other pests
2.8.1 Fire ants
2.8.2 Spider mites
2.8.3 Mites
2.8.4 Locusts
2.8.5 Termites
2.9 Patent applications
2.9.1 Insects
2.9.2 Nematodes
2.10 References and resources
3. RNAi in other crop sectors
3.1 Summary
3.2 Introduction
3.3 Control of diseases
3.3.1 Viruses
3.3.2 Progress with RNAi for disease control
3.3.3 Disease control patent applications
3.4 Control of weeds
3.4.1 Overcoming herbicide resistance
3.4.2 Control of parasitic weeds by RNAi
3.5 Crop enhancement
3.5.1 Modified oil composition
3.5.2 Reduced lignin
3.5.3 Abiotic stress
3.5.4 Enzymatic browning
3.5.5 Crop Enhancement patent applications
3.6 References and resources
4. Formulation and delivery of RNAi
4.1 Summary
4.2 Introduction
4.3 Principles
4.3.1 Knowledge base from human therapeutics
4.3.2 Progress in crop protection and pest control
4.3.3 Collaborations
4.4 Patent activity
4.5 References and resources
5. Crop protection companies
5.1 Summary
5.2 Introduction
5.3 BASF
5.3.1 Modified starch potatoes
5.3.2 Disease control
5.3.3 Nematode control
5.3.4 Weed control
5.4 Bayer CropScience
5.4.1 Collaborations
5.4.2 Patent applications
5.5 Dow AgroSciences
5.6 DuPont
5.7 Monsanto
5.7.1 Low lignin alfalfa
5.7.2 SmartStax Pro (MON87411)
5.7.3 BioDirect
5.7.4 Rosetta Green acquisition
5.7.5 Preceres and RNAi delivery R&D
5.7.6 Patent applications
5.8 Syngenta
5.8.1 Collaborations
5.8.2 Patent applications
5.9 References and resources
6. Specialist RNAi technology companies and institutes
6.1 Summary
6.2 Introduction
6.3 Alnylam Pharmaceuticals
6.4 Arbutus Biopharma
6.5 CSIRO
6.6 Evogene
6.7 Forage Genetics
6.8 Forrest Innovations
6.9 Fraunhofer Institute for Molecular Biology and Applied Ecology
6.10 Ghent University
6.11 Iden Biotechnology
6.12 Intrexon
6.13 J. R. Simplot
6.14 Okanagan Specialty Fruits
6.15 Nemgenix
6.16 Performance Plants
6.17 PhaseRx
6.18 Preceres
6.19 University of Cambridge
6.20 University of Nebraska
6.21 Tekmira
6.22 Venganza
6.23 References and resources
For more information about this report visit https://www.researchandmarkets.com/research/mwvrrr/rnai_technology
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Crop Farming


Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 



